Adeno-associated virus

Gene Therapy in Lung Disease

Volumn , Issue , 2002, Pages 51-92

  Duan, Dongsheng ^a   Yue, Yongping ^a   Engelhardt, John F ^b  

^a University of Missouri   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4544352490     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (252)

1. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1:91-99.
2. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7:33-40.
3. High KA. Gene therapy: a 2001 perspective. Haemophilia 2001; 7(Suppl) 1:23-27.
4. Berns KI, Giraud C. Adeno-associated virus (AAV) vectors in gene therapy. Current Topics in Microbiology and Immunology, 218. Berlin: Springer, 1996:vi, 173.
5. Tobiasch E, Rabreau M, Geletneky K, et al. Detection of adeno-associated virus DNA in human genital tissue and in material from spontaneous abortion. J Med Virol 1994; 44:215-222.
6. Schlehofer JR. The tumor suppressive properties of adeno-associated viruses. Mutat Res 1994; 305:303-313.
7. Tezak Z, Nagaraju K, Plotz P, Hoffman EP. Adeno-associated virus in normal and myositis human skeletal muscle. Neurology 2000; 55:1913-1917.
8. Summerford C, Samulski RJ. Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat Med 1999; 5:587-588.
9. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72:2224-2232.
10. Matsushita T, Elliger S, Elliger C, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998; 5:938-945.
11. Collaco RF, Cao X, Trempe JP. A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 1999; 238:397-405.
12. Duan D, Yue Y, Yan Z, Engelhardt JF. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med 2000; 6:595-598.
13. Yan Z, Zhang Y, Duan D, Engelhardt JF. From the Cover: Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA 2000; 97:6716-6721.
14. Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 2000; 6:599-602.
15. Nakai H, Storm TA, Kay MA. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors (see Comments). Nat Biotechnol 2000; 18:527-532.
16. Duan D, Yue Y, Yan Z, McCray PB, Engelhardt JF. Polarity Influences the efficiency of recombinant adeno-associated virus infection in differentiated airway epithelia. Hum Gene Ther 1998; 9:2761-2776.
17. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105:1573-1587.
18. Meyers C, Mane M, Kokorina N, Alam S, Hermonat PL. Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model. Virology 2000; 272:338-346.
19. Fisher RE, Mayor HD. The evolution of defective and autonomous parvoviruses. J Theor Biol 1991; 149:429-39.
20. Fisher RE, Mayor HD. Evolution of a defective virus from a cellular defense mechanism. J Theor Biol 1986; 118:395-404.
21. Atchison RW, Casto BC, Hammon WM. Electron microscopy of adenovirus-associated virus (AAV) in cell cultures. Virology 1966; 29:353-357.
22. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci USA 1966; 55:1467-1474.
23. Lipps BV, Mayor HD. Characterization of heavy particles of adeno-associated virus type 1. J Gen Virol 1982; 58(Pt 1):63-72.
24. de la Maza LM, Carter BJ. Heavy and light particles of adeno-associated virus. J Virol 1980; 33:1129-1137.
25. Linden RM, Berns KI. Molecular biology of adeno-associated viruses. Contrib Microbiol 2000; 4:68-84.
26. Mayor HD, Torikai K, Melnick JL, Mandel M. Plus and minus single-stranded DNA separately encapsidated in adeno-associated satellite virions. Science 1969; 166:1280-1282.
27. Berns KI, Adler S. Separation of two types of adeno-associated virus particles containing complementary polynucleotide chains. J Virol 1972; 9:394-396.
28. Samulski RJ, Chang LS, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol 1987; 61:3096-3101.
29. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992; 158:97-129.
30. Turnbull AE, Skulimowski A, Smythe JA, Alexander IE. Adeno-associated virus vectors show variable dependence on divalent cations for thermostability: implications for purification and handling. Hum Gene Ther 2000; 11:629-635.
31. Blacklow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst 1968; 40:319-327.
32. Boucher DW, Parks WP, Melnick JL. A sensitive neutralization test for the adeno-associated satellite viruses. J Immunol 1970; 104:555-559.
33. Rosenbaum MJ, Edwards EA, Pierce WE, Peckinpaugh RO, Parks WP, Melnick JL. Serologic surveillance for adeno-associated satellite virus antibody in military recruits. J Immunol 1971; 106:711-720.
34. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6:1574-1583.
35. Schlehofer JR, Dupressoir T. Infectiology and pathology of human adeno-associated viruses. Contrib Microbiol 2000; 4:59-67.
36. Bantel-Schaal U, zur Hausen H. Characterization of the DNA of a defective human parvovirus isolated from a genital site. Virology 1984; 134:52-63.
37. Agbandje-McKenna M, Llamas-Saiz AL, Wang F, Tattersall P, Rossmann MG. Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure 1998; 6:1369-1381.
38. Walters RW, Moninger T, Olson N, et al. Structural studies of adeno-associated virus serotype 5. Mol Ther 2001; 3:S184.
39. Kronenberg S, Kleinschmidt JA, Bottcher B. Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep 2001; 2:997-1002.
40. Girod A, Ried M, Wobus C, et al. Genetic capsid modifications allow efficient retargeting of adeno-associated virus type 2. Nat Med 1999; 5:1052-1056.
41. Rabinowitz JE, Xiao W, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 1999; 265:274-285.
42. Moskalenko M, Chen L, van Roey M, et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000; 74:1761-1766.
43. Wobus CE, Hugle-Dorr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol 2000; 74:9281-9293.
44. Wu P, Xiao W, Conlon T, et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000; 74:8635-8647.
45. Im DS, Muzyczka N. The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell 1990; 61:447-457.
46. Smith RH, Kotin RM. The Rep52 gene product of adeno-associated virus is a DNA helicase with 3’-to-5’ polarity. J Virol 1998; 72:4874-4881.
47. Prasad KM, Trempe JP. The adeno-associated virus Rep78 protein is covalently linked to viral DNA in a preformed virion. Virology 1995; 214:360-370.
48. Dubielzig R, King JA, Weger S, Kern A, Kleinschmidt JA. Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes. J Virol 1999; 73:8989-8998.
49. Beaton A, Palumbo P, Berns KI. Expression from the adeno-associated virus p5 and p19 promoters is negatively regulated in trans by the rep protein. J Virol 1989; 63:4450-4454.
50. Pereira DJ, McCarty DM, Muzyczka N. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J Virol 1997; 71:1079-1088.
51. Balague C, Kalla M, Zhang WW. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 1997; 71:3299-3306.
52. Surosky RT, Urabe M, Godwin SG, et al. Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 1997; 71: 7951-9.
53. Chejanovsky N, Carter BJ. Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication. Virology 1989; 173:120-128.
54. King JA, Dubielzig R, Grimm D, Kleinschmidt JA. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J 2001; 20:3282-3291.
55. Li J, Samulski RJ, Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol 1997; 71:5236-5243.
56. Vincent KA, Piraino ST, Wadsworth SC. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J Virol 1997; 71: 1897-1905.
57. Salvetti A, Oreve S, Chadeuf G, et al. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998; 9:695-706.
58. Lusby E, Fife KH, Berns KI. Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA. J Virol 1980; 34:402-409.
59. Zhang MQ. Statistical features of human exons and their flanking regions. Hum Mol Genet 1998; 7:919-932.
60. Ren J, Qu X, Chaires JB, Trempe JP, Dignam SS, Dignam JD. Spectral and physical characterization of the inverted terminal repeat DNA structure from adeno-associated virus 2. Nucleic Acids Res 1999; 27:1985-1990.
61. Chou SH, Tseng YY, Chu BY. Natural abundance heteronuclear NMR studies of the T3 mini-loop hairpin in the terminal repeat of the adenoassociated virus 2. J Biomol NMR 2000; 17:1-16.
62. Linden RM, Winocour E, Berns KI. The recombination signals for adeno-associated virus site-specific integration. Proc Natl Acad Sci USA 1996; 93:7966-7972.
63. Meneses P, Berns KI, Winocour E. DNA sequence motifs which direct adeno-associated virus site-specific integration in amodel system. J Virol 2000; 74:6213-6216.
64. Weitzman MD, Kyostio SR, Kotin RM, Owens RA. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 1994; 91:5808-5812.
65. Wang XS, Ponnazhagan S, Srivastava A. Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions. J Virol 1996; 70:1668-1677.
66. Wang XS, Qing K, Ponnazhagan S, Srivastava A. Adeno-associated virus type 2 DNA replication in vivo: mutation analyses of the D sequence in viral inverted terminal repeats. J Virol 1997; 71:3077-3082.
67. Xiao X, Xiao W, Li J, Samulski RJ. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol 1997; 71:941-948.
68. Qing K, Wang XS, Kube DM, Ponnazhagan S, Bajpai A, Srivastava A. Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc Natl Acad Sci USA 1997; 94:10879-10884.
69. Qing K, Khuntirat B, Mah C, et al. Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J Virol 1998; 72:1593-1599.
70. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72:1438-1445.
71. Walters RW, Yi SM, Keshavjee S, et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 2001; 21:21.
72. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5:78-82.
73. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999; 5:71-77.
74. Qiu J, Mizukami H, Brown KE. Adeno-associated virus 2 co-receptors? (letter). Nat Med 1999; 5:467-468.
75. Duan D, Li Q, Kao AW, Yue Y, Pessin JE, Engelhardt JF. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 1999; 73:10371-10376.
76. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 2000; 74:2777-2785.
77. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T, Engelhardt JF. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol 2000; 74:9184-9196.
78. Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 2000; 74:992-996.
79. Hansen J, Qing K, Srivastava A. Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts. J Virol 2001; 75:4080-4090.
80. Carter BJ. Adeno-associated virus vectors. Curr Opin Biotechnol 1992; 3:533-539.
81. Myers MW, Laughlin CA, Jay FT, Carter BJ. Adenovirus helper function for growth of adeno-associated virus: effect of temperature-sensitive mutations in adenovirus early gene region 2. J Virol 1980; 35:65-75.
82. Mishra L, Rose JA. Adeno-associated virus DNA replication is induced by genes that are essential for HSV-1 DNA synthesis. Virology 1990; 179:632-639.
83. Weindler FW, Heilbronn R. A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol 1991; 65:2476-2483.
84. Weitzman MD, Fisher KJ, Wilson JM. Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers. J Virol 1996; 70:1845-1854.
85. Greber UF. Virus assembly and disassembly: the adenovirus cysteine protease as a trigger factor. Rev Med Virol 1998; 8:213-222.
86. Ruffing M, Zentgraf H, Kleinschmidt JA. Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells. J Virol 1992; 66:6922-6930.
87. Hoque M, Ishizu K, Matsumoto A, et al. Nuclear transport of the major capsid protein is essential for adeno-associated virus capsid formation. J Virol 1999; 73: 7912-7915.
88. Myers MW, Carter BJ. Assembly of adeno-associated virus. Virology 1980; 102: 71-82.
89. Wistuba A, Weger S, Kern A, Kleinschmidt JA. Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J Virol 1995; 69:5311-5319.
90. Henry CJ, Merkow LP, Pardo M, McCabe C. Electron microscope study on the replication of AAV-1 in herpes-infected cells. Virology 1972; 49:618-621.
91. Ding L, Lu S, Munshi NC. In vitro packaging of an infectious recombinant adeno-associated virus 2. Gene Ther 1997; 4:1167-1172.
92. Zhou X, Muzyczka N. In vitro packaging of adeno-associated virus DNA. J Virol 1998; 72:3241-3247.
93. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87:2211-2215.
94. Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19 (published erratum appears in EMBO J 1992; 11[3]:1228). Embo J 1991; 10:3941-3950.
95. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992; 11:5071-5078.
96. Samulski RJ. Adeno-associated virus: integration at a specific chromosomal locus. Curr Opin Genet Dev 1993; 3:74-80.
97. Berns KI. The Gordon Wilson Lecture. From basic virology to human gene therapy. Trans Am Clin Climatol Assoc 1999; 110:75-85.
98. Dyall J, Berns KI. Site-specific integration of adeno-associated virus into an episome with the target locus via a deletion-substitution mechanism. J Virol 1998; 72:6195-6198.
99. Berns KI, Linden RM. The cryptic life style of adeno-associated virus. Bioessays 1995; 17:237-245.
100. Giraud C, Winocour E, Berns KI. Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence. Proc Natl Acad Sci USA 1994; 91: 10039-10043.
101. Giraud C, Winocour E, Berns KI. Recombinant junctions formed by site-specific integration of adeno-associated virus into an episome. J Virol 1995; 69:6917-6924.
102. Linden RM, Ward P, Giraud C, Winocour E, Berns KI. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1996; 93:11288-11294.
103. Linden RM, Berns KI. Site-specific integration by adeno-associated virus: a basis for a potential gene therapy vector (editorial). Gene Ther 1997; 4:4-5.
104. Dyall J, Szabo P, Berns KI. Adeno-associated virus (AAV) site-specific integration: formation of AAV-AAVS1 junctions in an in vitro system. Proc Natl Acad Sci USA 1999; 96:12849-12854.
105. Rizzuto G, Gorgoni B, Cappelletti M, et al. Development of animal models for adeno-associated virus site-specific integration. J Virol 1999; 73:2517-2526.
106. Young SM, Jr., McCarty DM, Degtyareva N, Samulski RJ. Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol 2000; 74:3953-3966.
107. Das HK, Jackson CL, Miller DA, Leff T, Breslow JL. The human apolipoprotein C-II gene sequence contains a novel chromosome 19-specific minisatellite in its third intron. J Biol Chem 1987; 262:4787-4793.
108. Lamartina S, Sporeno E, Fattori E, Toniatti C. Characteristics of the adeno-associated virus preintegration site in human chromosome 19: open chromatin conformation and transcription-competent environment. J Virol 2000; 74:7671-7677.
109. Dutheil N, Shi F, Dupressoir T, Linden RM. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci USA 2000; 97:4862-4866.
110. Kotin RM, Menninger JC, Ward DC, Berns KI. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 1991; 10:831-834.
111. Rutledge EA, Russell DW. Adeno-associated virus vector integration junctions. J Virol 1997; 71:8429-8436.
112. Yang CC, Xiao X, Zhu X, et al. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J Virol 1997; 71:9231-9247.
113. Palombo F, Monciotti A, Recchia A, Cortese R, Ciliberto G, La Monica N, Sitespecific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector. J Virol 1998; 72:5025-5034.
114. Pieroni L, Fipaldini C, Monciotti A, et al. Targeted integration of adeno-associated virus-derived plasmids in transfected human cells. Virology 1998; 249:249-259.
115. Recchia A, Parks RJ, Lamartina S, et al. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci USA 1999; 96:2615-2620.
116. Nakai H, Iwaki Y, Kay MA, Couto LB. Isolation of recombinant adeno-associated virus vector-cellular DNAjunctions frommouse liver. J Virol 1999; 73:5438-5447.
117. Wonderling RS, Owens RA. Binding sites for adeno-associated virus Rep proteins within the human genome. J Virol 1997; 71:2528-2534.
118. Lamartina S, Ciliberto G, Toniatti C. Selective cleavage of AAVS1 substrates by the adeno-associated virus type 2 rep68 protein is dependent on topological and sequence constraints. J Virol 2000; 74:8831-8842.
119. Fisher-Adams G, Wong KK, Jr., Podsakoff G, Forman SJ, Chatterjee S. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood 1996; 88:492-504.
120. Kearns WG, Afione SA, Fulmer SB, et al. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther 1996; 3:748-755.
121. Ponnazhagan S, Erikson D, Kearns WG, et al. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum Gene Ther 1997; 8:275-284.
122. Lamartina S, Roscilli G, Rinaudo D, Delmastro P, Toniatti C. Lipofection of purified adeno-associated virus Rep68 protein: toward a chromosome-targeting nonviral particle. J Virol 1998; 72:7653-7658.
123. Handa H, Carter BJ. Adeno-associated virus DNA replication complexes in herpes simplex virus or adenovirus-infected cells. J Biol Chem 1979; 254:6603-6610.
124. Snyder RO, Im DS, Muzyczka N. Evidence for covalent attachment of the adeno-associated virus (AAV) rep protein to the ends of the AAV genome. J Virol 1990; 64:6204-6213.
125. Ni TH, McDonald WF, Zolotukhin I, et al. Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. J Virol 1998; 72:2777-2787.
126. Hermonat PL, Santin AD, Carter CA, Parham GP, Quirk JG. Multiple cellular proteins are recognized by the adeno-associated virus Rep78 major regulatory protein and the amino-half of Rep78 is required for many of these interactions. Biochem Mol Biol Int 1997; 43:409-420.
127. Costello E, Saudan P, Winocour E, Pizer L, Beard P. High mobility group chromosomal protein 1 binds to the adeno-associated virus replication protein (Rep) and promotes Rep-mediated site-specific cleavage of DNA, ATPase activity and transcriptional repression. EMBO J 1997; 16:5943-5954.
128. Chiorini JA, Afione S, Kotin RM. Adeno-associated virus (AAV) type 5 Rep protein cleaves a unique terminal resolution site compared with other AAV serotypes. J Virol 1999; 73:4293-4298.
129. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70:520-532.
130. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70:3227-3234.
131. Sanlioglu S, Duan D, Engelhardt JF. Two independent molecular pathways for recombinant Adeno-Associated virus genome conversion occur after UV-C and E4orf6 augmentation of transduction. Hum Gene Ther 1999; 10:591-602.
132. Mah C, Qing K, Khuntirat B, et al. Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J Virol 1998; 72:9835-9843.
133. Nakai H, Storm TA, Kay MA. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol 2000; 74:9451-9463.
134. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long term episomal persistence in muscle. J Virol 1998; 72:8568-8577.
135. Duan D, Sharma P, Dudus L, et al. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression. J Virol 1999; 73:161-169.
136. Duan D, Yan Z, Yue Y, Engelhardt JF. Structural analysis of adeno-associated virus transduction intermediates. Virology 1999; 261:8-14.
137. Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994; 11:517-521.
138. Afione SA, Conrad CK, Kearns WG, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996; 70:3235-3241.
139. Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, Engelhardt JF. Concatamerization of adeno-associated viral circular genomes occurs through intermolecular recombination. J Virol 1999; 73:9468-9477.
140. Vincent-Lacaze N, Snyder RO, Gluzman R, Bohl D, Lagarde C, Danos O. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J Virol 1999; 73:1949-1955.
141. Musatov SA, Scully TA, Dudus L, Fisher KJ. Induction of circular episomes duringrescue and replication of adeno-associated virus in experimental models of virus latency. Virology 2000; 275:411-432.
142. Tsunoda H, Hayakawa T, Sakuragawa N, Koyama H. Site-specific integration of adeno-associated virus-based plasmid vectors in lipofected HeLa cells. Virology 2000; 268:391-401.
143. Song S, Laipis PJ, Berns KI, Flotte TR. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci USA 2001; 98:4084-4088.
144. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3:306-312.
145. Miao CH, Snyder RO, Schowalter DB, et al. The kinetics of rAAV integration in the liver (letter). Nat Genet 1998; 19:13-15.
146. Wu P, Phillips MI, Bui J, Terwilliger EF. Adeno-associated virus vector-mediated transgene integration into neurons and other nondividing cell targets. J Virol 1998; 72:5919-5926.
147. Omori F, Messner HA, Ye C, et al. Nontargeted stable integration of recombinant adeno-associated virus into human leukemia and lymphoma cell lines as evaluated by fluorescence in situ hybridization. Hum Gene Ther 1999; 10:537-543.
148. Rivadeneira ED, Popescu NC, Zimonjic DB, et al. Sites of recombinant adeno-associated virus integration. Int J Oncol 1998; 12:805-810.
149. Holscher C, Horer M, Kleinschmidt JA, Zentgraf H, Burkle A, Heilbronn R. Cell lines inducibly expressing the adeno-associated virus (AAV) rep gene: requirements for productive replication of rep-negative AAV mutants. J Virol 1994; 68: 7169-7177.
150. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 1995; 6:1329-1341.
151. Tamayose K, Hirai Y, Shimada T. A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum Gene Ther 1996; 7:507-513.
152. Grimm D, Kleinschmidt JA. Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Hum Gene Ther 1999; 10:2445-2450.
153. Schmidt M, Afione S, Kotin RM. Adeno-associated virus type 2 Rep78 induces apoptosis through caspase activation independently of p53. J Virol 2000; 74:9441-9450.
154. Bertran J, Yang Y, Hargrove P, Vanin EF, Nienhuis AW. Targeted integration of a recombinant globin gene adeno-associated viral vector into human chromosome 19. Ann NY Acad Sci 1998; 850:163-177.
155. Satoh W, Hirai Y, Tamayose K, Shimada T. Site-specific integration of an adeno-associated virus vector plasmid mediated by regulated expression of rep based on CreloxP recombination. J Virol 2000; 74:10631-10638.
156. Davis MD, Wonderling RS, Walker SL, Owens RA. Analysis of the effects of charge cluster mutations in adeno-associated virus Rep68 protein in vitro. J Virol 1999; 73:2084-2093.
157. Rinaudo D, Lamartina S, Roscilli G, Ciliberto G, Toniatti C. Conditional sitespecific integration into human chromosome 19 by using a ligand-dependent chimeric adeno-associated virus/Rep protein. J Virol 2000; 74:281-294.
158. Cathomen T, Collete D, Weitzman MD. A chimeric protein containing the N terminus of the adeno-associated virus Rep protein recognizes its target site in an in vivo assay. J Virol 2000; 74:2372-2382.
159. Yoon M, Smith DH, Ward P, Medrano FJ, Aggarwal AK, Linden RM. Amino-terminal domain exchange redirects origin-specific interactions of adeno-associated virus rep78 in vitro. J Virol 2001; 75:3230-3239.
160. Blacklow NR, Hoggan MD, Kapikian AZ, Austin JB, Rowe WP. Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol 1968; 88:368-378.
161. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 1997; 71:5932-5941.
162. Halbert CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 1998; 72:9795-9805.
163. Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998; 72: 309-319.
164. Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 2000; 74:1524-1532.
165. Halbert CL, Allen JM, Miller AD. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 2001; 75:6615-6624.
166. Beck SE, Jones LA, Chesnut K, et al. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol 1999; 73:9446-9455.
167. Anand V, Chirmule N, Fersh M, Maguire AM, Bennett J. Additional transduction events after subretinal readministration of recombinant adeno-associated virus. Hum Gene Ther 2000; 11:449-457.
168. Chirmule N, Xiao W, Truneh A, et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000; 74:2420-2425.
169. Xiao W, Chirmule N, Schnell MA, Tazelaar J, Hughes JV, Wilson JM. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther 2000; 1:323-329.
170. Ge Y, Powell S, Van Roey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 2001; 97:3733-3737.
171. Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N, Wilson JM. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001; 75:6199-6203.
172. Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol 1999; 73:8549-8558.
173. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72:4212-4223.
174. Zhang Y, Chirmule N, Gao G, Wilson J. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J Virol 2000; 74:8003-8010.
175. Xin KQ, Urabe M, Yang J, et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther 2001; 12:1047-1061.
176. Cordier L, Gao GP, Hack AA, et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 2001; 12:205-215.
177. Duan D, Yan Z, Yue Y, Ding W, Engelhardt JF. Enhancement of muscle gene delivery with pseudotyped AAV-5 correlates with myoblast differentiation. J Virol 2001; 75:7662-7671.
178. McLaughlin SK, Collis P, Hermonat PL, Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol 1988; 62:1963-1973.
179. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63:3822-3828.
180. Gao GP, Wilson JM, Wivel NA. Production of recombinant adeno-associated virus. Adv Virus Res 2000; 55:529-543.
181. Cao L, Liu Y, During MJ, Xiao W. High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J Virol 2000; 74:11456-11463.
182. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998; 9:2745-2760.
183. Gao GP, Qu G, Faust LZ, et al. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998; 9:2353-2362.
184. Inoue N, Russell DW. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J Virol 1998; 72:7024-7031.
185. Liu XL, Clark KR, Johnson PR. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther 1999; 6:293-299.
186. Johnston KM, Jacoby D, Pechan PA, et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 1997; 8:359-370.
187. Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J Virol 1997; 71: 8780-8789.
188. Ferrari FK, Xiao X, McCarty D, Samulski RJ. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat Med 1997; 3:1295-1297.
189. Clark KR, Liu X, McGrath JP, Johnson PR. Highly purified recombinant adeno associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 1999; 10:1031-1039.
190. Anderson R, Macdonald I, Corbett T, Whiteway A, Prentice HG. A method for the preparation of highly purified adeno-associated virus using affinity column chromatography, protease digestion and solvent extraction. J Virol Methods 2000; 85:23-34.
191. Debelak D, Fisher J, Iuliano S, Sesholtz D, Sloane DL, Atkinson EM. Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2. J Chromatogr B Biomed Sci Appl 2000; 740:195-202.
192. O’Riordan CR, Lachapelle AL, Vincent KA, Wadsworth SC. Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV). J Gene Med 2000; 2:444-454.
193. Gao G, Qu G, Burnham MS, et al. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther 2000; 11:2079-2091.
194. Auricchio A, Hildinger M, O’Connor E, Gao GP, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 2001; 12:71-76.
195. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8:148-154.
196. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000; 20:4686-4700.
197. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28:92-95.
198. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24:257-261.
199. Greelish JP, Su LT, Lankford EB, et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 1999; 5:439-443.
200. Xiao X, Li J, Tsao YP, Dressman D, Hoffman EP, Watchko JF. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol 2000; 74:1436-1442.
201. Cordier L, Hack AA, Scott MO, et al. Rescue of skeletal muscles of gamma-sarco-glycan-deficient mice with adeno-associated virus-mediated gene transfer. Mol Ther 2000; 1:119-129.
202. Stedman H, Wilson JM, Finke R, Kleckner AL, Mendell J. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum Gene Ther 2000; 11:777-790.
203. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000; 97:13714-13719.
204. During MJ, Xu R, Young D, Kaplitt MG, Sherwin RS, Leone P. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med 1998; 4:1131-1135.
205. Lee HC, Kim SJ, Kim KS, Shin HC, Yoon JW. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature 2000; 408: 483-488.
206. During MJ, Symes CW, Lawlor PA, et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 2000; 287:1453-1460.
207. Duan D, Zhang Y, Engelhardt JF. Gene delivery to the airway. In: Dracopoli NC, Haines JL, Korf BR, et al., eds. Current Protocols in Human Genetics. New York: Wiley, 1998:13.9.1-13.9.34.
208. Walters RW, Duan D, Engelhardt JF, Welsh MJ. Incorporation of adeno-associated virus in a calcium phosphate coprecipitate improves gene transfer to airway epithelia in vitro and in vivo. J Virol 2000; 74:535-540.
209. Weiss DJ, Bonneau L, Allen JM, Miller AD, Halbert CL. Perfluorochemical liquid enhances adeno-associated virus-mediated transgene expression in lungs. Mol Ther 2000; 2:624-630.
210. Engelhardt JF, Schlossberg H, Yankaskas JR, Dudus L. Progenitor cells of the adult human airway involved in submucosal gland development. Development 1995; 121:2031-2046.
211. Duan D, Sehgal A, Yao J, Engelhardt JF. Lef1 Transcription factor expression defines airway progenitor cell targets for in utero gene therapy of submucosal gland in cystic fibrosis. Am J Respir Cell Mol Biol 1998; 18:750-758.
212. Borthwick DW, West JD, Keighren MA, Flockhart JH, Innes BA, Dorin JR. Murine submucosal glands are clonally derived and show a cystic fibrosis gene-dependent distribution pattern. Am J Respir Cell Mol Biol 1999; 20:1181-1189.
213. Duan D, Yue Y, Zhou W, et al. Submucosal Gland Development in the Airway is Controlled by Lymphoid Enhancer Binding Factor-1 (Lef-1). Development 1999; 126:4441-4453.
214. Conrad CK, Allen SS, Afione SA, et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 1996; 3:658-668.
215. Rubenstein RC, McVeigh U, Flotte TR, Guggino WB, Zeitlin PL. CFTR gene transduction in neonatal rabbits using an adeno-associated virus (AAV) vector. Gene Ther 1997; 4:384-392.
216. Kitson C, Angel B, Judd D, et al. The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium. Gene Ther 1999; 6:534-546.
217. Zabner J, Zeiher BG, Friedman E, Welsh MJ. Adenovirus-mediated gene transfer to ciliated airway epithelia requires prolonged incubation time. J Virol 1996; 70: 6994-7003.
218. Duan D, Yue Y, Engelhardt JF. Response to “polarity influences the efficiency of recombinant adeno-associated virus infection in differentiated airway epithelia.” Hum Gene Ther 1999; 10:1553-1557.
219. Zabner J, Seiler M, Walters R, et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74:3852-3858.
220. Engelhardt JF, Yang Y, Stratford-Perricaudet LD, et al. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet 1993; 4:27-34.
221. Goldman MJ, Wilson JM. Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J Virol 1995; 69: 5951-5958.
222. Zabner J, Freimuth P, Puga A, Fabrega A, Welsh MJ. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. J Clin Invest 1997; 100:1144-1149.
223. Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, Boucher RC. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J Virol 1998; 72:6014-6023.
224. Walters RW, Grunst T, Bergelson JM, Finberg RW, Welsh MJ, Zabner J. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem 1999; 274:10219-10226.
225. Pickles RJ, Fahrner JA, Petrella JM, Boucher RC, Bergelson JM. Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer. J Virol 2000; 74:6050-6057.
226. Wang G, Davidson BL, Melchert P, et al. Efficient gene transfer to differentiated human airway epithelia with recombinant amphotropic and xenotropic retroviruses. J Virol 1998; 72:9818-9826.
227. Virella-Lowell I, Poirier A, Chesnut KA, Brantly M, Flotte TR. Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Ther 2000; 7:1783-1789.
228. Bals R, Xiao W, Sang N, Weiner DJ, Meegalla RL, Wilson JM. Transduction of well-differentiated airway epithelium by recombinant adeno-associated virus is limited by vector entry. J Virol 1999; 73:6085-6088.
229. Alexander IE, Russell DW, Miller AD. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol 1994; 68:8282-8287.
230. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci USA 1995; 92:5719-5723.
231. Teramoto S, Bartlett JS, McCarty D, Xiao X, Samulski RJ, Boucher RC. Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: comparison with adenovirus vectors. J Virol 1998; 72:8904-8912.
232. Baumeister W, Walz J, Zuhl F, Seemuller E. The proteasome: paradigm of a selfcompartmentalizing protease. Cell 1998; 92:367-380.
233. Strous GJ, Govers R. The ubiquitin-proteasome system and endocytosis. J Cell Sci 1999; 112:1417-1423.
234. Leach CL, Greenspan JS, Rubenstein SD, et al. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group. N Engl J Med 1996; 335:761-767.
235. Lisby DA, Ballard PL, Fox WW, Wolfson MR, Shaffer TH, Gonzales LW. Enhanced distribution of adenovirus-mediated gene transfer to lung parenchyma by perfluorochemical liquid. Hum Gene Ther 1997; 8:919-928.
236. Weiss DJ, Strandjord TP, Jackson JC, Clark JG, Liggitt D. Perfluorochemical liquid-enhanced adenoviral vector distribution and expression in lungs of spontaneously breathing rodents. Exp Lung Res 1999; 25:317-333.
237. Weiss DJ, Strandjord TP, Liggitt D, Clark JG. Perflubron enhances adenovirus-mediated gene expression in lungs of transgenic mice with chronic alveolar filling. Hum Gene Ther 1999; 10:2287-2293.
238. Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 1996; 7:2101-2112.
239. Flotte TR, Afione SA, Solow R, et al. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem 1993; 268:3781-3790.
240. Duan D, Yue Y, Yan Z, Engelhardt JF. Trans-splicing vectors expand the packaging limits of adeno-associated virus for gene therapy applications. In: Machida CA, ed. Methods in Molecular Medicine, Viral Vectors for Gene Therapy Methods and Protocols. Totowa, NJ: Humana Press, 2002. In press.
241. Phelps SF, Hauser MA, Cole NM, et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995; 4:1251-1258.
242. Zhang L, Wang D, Fischer H, et al. Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes. Proc Natl Acad Sci USA 1998; 95:10158-10163.
243. Wang D, Fischer H, Zhang L, Fan P, Ding RX, Dong J. Efficient CFTR expression from AAV vectors packaged with promoters—the second generation. Gene Ther 1999; 6:667-675.
244. Flotte T, Carter B, Conrad C, et al. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7:1145-1159.
245. Wagner JA, Gardner P. Toward cystic fibrosis gene therapy. Annu Rev Med 1997; 48:203-216.
246. Wagner JA, Moran ML, Messner AH, et al. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther 1998; 9:889-909.
247. Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus (letter). Lancet 1998; 351:1702-1703.
248. Wagner JA, Messner AH, Moran ML, et al. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999; 109:266-274.
249. Wagner JA, Nepomuceno IB, Shah N, et al. Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. J Gene Med 1999; 1:13-21.
250. Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature 2001; 412:914-917.
251. Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001; 8:1343-1346.
252. Harper SQ, Hauser MA, DelloRusso C, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002; 8: 253-261.